Neuropilins and use thereof in methods for diagnosis and prognosis of cancer
    6.
    发明授权
    Neuropilins and use thereof in methods for diagnosis and prognosis of cancer 有权
    神经胶质蛋白及其在癌症诊断和预后方法中的应用

    公开(公告)号:US06635421B1

    公开(公告)日:2003-10-21

    申请号:US09583638

    申请日:2000-05-30

    IPC分类号: C12Q168

    CPC分类号: C07K14/71 A61K38/00 A61K48/00

    摘要: The present invention relates to VEGF receptors (VEGFR) and neuropilins such as VEGF165R/NP-1 and NP-2 that are associated with metastatic potential of a malignant cell and their use in the diagnosis and prognosis of cancer. Preferred ones are VEGF165R/NP-1 and NP-2 but any neuropilin or VEGFR, where the constituents share at least about 85% homology with either of the above VEGF165R/NP-1 and NP-2 can be used. More preferably, such constituent shares at least 90% homology. Still more preferably, each constituent shares at least 95% homology.

    摘要翻译: 本发明涉及与恶性细胞转移潜能相关的VEGF受体(VEGFR)和神经胶质蛋白如VEGF165R / NP-1和NP-2及其在诊断和预后中的用途。 优选的是VEGF165R / NP-1和NP-2,但是可以使用任何神经蛋白或VEGFR,其中组分与上述VEGF165R / NP-1和NP-2中的任一个具有至少约85%的同源性。 更优选地,这样的成分具有至少90%的同源性。 更优选地,每个成分具有至少95%的同源性。

    Pharmaceutical compositions comprising peptide antagonists of vascular endothelial growth factor
    7.
    发明授权
    Pharmaceutical compositions comprising peptide antagonists of vascular endothelial growth factor 有权
    包含血管内皮生长因子的肽拮抗剂的药物组合物

    公开(公告)号:US08889620B2

    公开(公告)日:2014-11-18

    申请号:US13365373

    申请日:2012-02-03

    摘要: The present invention provides isolated polypeptides having VEGF antagonist activity, pharmaceutical compositions and methods of treatment. The polypeptides of the invention include polypeptides comprising a portion of SEQ ID NO: 1 having VEGF antagonist activity, polypeptides comprising SEQ ID NO: 2 or a portion thereof having VEGF antagonist activity, and a polypeptide having the structure of formula (I), set forth above. The present invention further includes analogs and derivatives of these polypeptides having VEGF antagonist activity.

    摘要翻译: 本发明提供具有VEGF拮抗剂活性的分离的多肽,药物组合物和治疗方法。 本发明的多肽包括包含具有VEGF拮抗剂活性的SEQ ID NO:1的一部分的多肽,包含SEQ ID NO:2的多肽或其具有VEGF拮抗剂活性的部分,以及具有式(I)结构的多肽, 以上。 本发明还包括具有VEGF拮抗剂活性的这些多肽的类似物和衍生物。

    Peptide antagonists of vascular endothelial growth factor and methods of use thereof
    9.
    发明授权
    Peptide antagonists of vascular endothelial growth factor and methods of use thereof 有权
    血管内皮生长因子的肽拮抗剂及其使用方法

    公开(公告)号:US08153585B2

    公开(公告)日:2012-04-10

    申请号:US12172491

    申请日:2008-07-14

    IPC分类号: A61K38/18 C07K14/475

    摘要: The present invention provides isolated polypeptides having VEGF antagonist activity, pharmaceutical compositions and methods of treatment of subjects having a disease or disorder associated with VEGF activity or subjects having tumors expressing a VEGF receptor. The polypeptides of the invention include polypeptides comprising a portion of SEQ ID NO: 1 having VEGF antagonist activity, polypeptides comprising SEQ ID NO: 2 or a portion thereof having VEGF antagonist activity, and a polypeptide having the structure of formula (I), set forth above. The present invention further includes analogs and derivatives of these polypeptides having VEGF antagonist activity.

    摘要翻译: 本发明提供具有VEGF拮抗剂活性的分离的多肽,药物组合物和治疗患有VEGF活性相关疾病或病症的受试者或具有表达VEGF受体的肿瘤的受试者的方法。 本发明的多肽包括包含具有VEGF拮抗剂活性的SEQ ID NO:1的一部分的多肽,包含SEQ ID NO:2的多肽或其具有VEGF拮抗剂活性的部分,以及具有式(I)结构的多肽, 以上。 本发明还包括具有VEGF拮抗剂活性的这些多肽的类似物和衍生物。

    Soluble inhibitors of vascular endothelial growth factor and use thereof
    10.
    发明申请
    Soluble inhibitors of vascular endothelial growth factor and use thereof 有权
    血管内皮生长因子的可溶性抑制剂及其用途

    公开(公告)号:US20080261867A1

    公开(公告)日:2008-10-23

    申请号:US11893633

    申请日:2007-08-17

    摘要: The present invention relates to cDNA encoding a soluble neuropilin protein (sNP) which is isolated from neuropilin (NP) producing cells or is recombinantly engineered from NP-encoding DNA. NP-1 and NP-2 are preferred NPs but any neuropilin or VEGF receptor (VEGFR), where the constituents share at least about 85% homology with either of the above VEGF165R/NP-1 and NP-2. More preferably, such constituent shares at least 90% homology. Still more preferably, each constituent shares at least 95% homology.

    摘要翻译: 本发明涉及编码可溶性神经蛋白蛋白(sNP)的cDNA,其从产生神经纤维蛋白(NP)的细胞中分离或从NP编码DNA重组工程改造。 NP-1和NP-2是优选的NP,但是任何神经纤维蛋白或VEGF受体(VEGFR),其中组分与上述VEGF 165 R / NP-1中的任一个具有至少约85%的同源性, NP-2。 更优选地,这样的成分具有至少90%的同源性。 更优选地,每个成分具有至少95%的同源性。